TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vicore Pharma Holding AB ( (SE:VICO) ) has provided an announcement.
Vicore Pharma announced its participation in the DNB Carnegie Nordic Healthcare Conference in Oslo, where CFO Hans Jeppsson will present and engage in one-on-one meetings. This participation underscores Vicore’s active engagement with the healthcare investment community, potentially enhancing its visibility and fostering strategic partnerships.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), with potential applications in respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Their lead program, buloxibutid, is an oral small molecule that has received Orphan Drug and Fast Track designation from the FDA and is currently in a Phase 2b trial.
Average Trading Volume: 677,464
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.33B
See more data about VICO stock on TipRanks’ Stock Analysis page.